Bayer plans filings for prostate cancer drug darolutamide

[cafead]

via Bayer is planning regulatory filings of darolutamide in prostate cancer following phase III trial results showing it helped prevent the disease from spreading, in a niche where Pfizer and Johnson & Johnson have already gained a foothold.

article source